Challenge
- A number of new treatment options have become available for relapse remitting multiple myeloma
- Currently unknown how new treatment options are being utilised in the real world amongst patients
Solution
- Treatment patterns study undertaken utilising prescription database in Germany
- Objective was to assess what treatments patients received following first-line bortezomib (protease inhibitor) therapy
Outcome
- Study found that many patients were receiving antibody therapies as second-line treatment, as a consequence, these treatments were no longer available to patients at later lines of treatment
- Overall treatment paradigm for a patient should be considered when planning treatment, with evidence delaying antibody treatments could increase overall survival
